Condition
Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Unknown1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06931002Not ApplicableRecruiting
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
NCT02102152Not ApplicableUnknownPrimary
Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
Showing all 2 trials